Hospital Corporation of China Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Hospital of China.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	19.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Hospital Corporation of China's (HKG:3869) Profit Is Only A Baseline For What They Can Achieve

Apr 29

Hospital Corporation of China Limited (HKG:3869) Stock Rockets 33% But Many Are Still Ignoring The Company

Jun 30

Hospital Corporation of China (HKG:3869) Hasn't Managed To Accelerate Its Returns

May 17

Does Hospital Corporation of China (HKG:3869) Have A Healthy Balance Sheet?

Apr 12

Would Shareholders Who Purchased Hospital Corporation of China's (HKG:3869) Stock Three Years Be Happy With The Share price Today?

Mar 08

Should You Be Impressed By Hospital Corporation of China's (HKG:3869) Returns on Capital?

Jan 14

Hospital Corporation of China (HKG:3869) Takes On Some Risk With Its Use Of Debt

Dec 10

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Hospital Corporation of China no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

SEHK:3869 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	1,428	131	67	83	N/A
9/30/2023	1,374	102	123	137	N/A
6/30/2023	1,320	73	179	192	N/A
3/31/2023	1,231	-204	153	167	N/A
12/31/2022	1,143	-481	126	143	N/A
9/30/2022	998	-424	81	96	N/A
6/30/2022	854	-367	36	49	N/A
3/31/2022	687	-324	77	91	N/A
12/31/2021	520	-281	117	133	N/A
9/30/2021	473	-245	132	146	N/A
6/30/2021	426	-210	146	159	N/A
3/31/2021	412	-307	110	121	N/A
12/31/2020	399	-404	73	83	N/A
9/30/2020	391	-435	75	86	N/A
6/30/2020	383	-467	76	88	N/A
3/31/2020	397	-158	64	76	N/A
12/31/2019	411	151	51	63	N/A
9/30/2019	414	110	57	72	N/A
6/30/2019	418	70	62	81	N/A
3/31/2019	401	10	77	102	N/A
12/31/2018	384	-50	91	122	N/A
6/30/2018	235	-53	30	49	N/A
3/31/2018	192	-40	38	48	N/A
12/31/2017	149	-27	46	47	N/A
6/30/2017	143	-5	N/A	75	N/A
3/31/2017	137	9	N/A	120	N/A
12/31/2016	131	23	N/A	164	N/A
9/30/2016	160	34	N/A	162	N/A
12/31/2015	143	51	N/A	7	N/A
12/31/2014	28	2	N/A	4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 3869 es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 3869 crezcan más rápidamente que el mercado Hong Kong

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 3869 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 3869 crezcan más rápidamente que el mercado de Hong Kong.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 3869 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 3869 se prevé que sea elevada dentro de 3 años.

Hospital Corporation of China Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Hospital Corporation of China Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

We Think Hospital Corporation of China's (HKG:3869) Profit Is Only A Baseline For What They Can Achieve

Hospital Corporation of China Limited, Annual General Meeting, Jun 20, 2024

New major risk - Financial position

Full year 2023 earnings released: EPS: CN¥0.96 (vs CN¥3.48 loss in FY 2022)

Hospital Corporation of China Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Investor sentiment improves as stock rises 26%

First half 2023 earnings released: EPS: CN¥0.91 (vs CN¥3.09 loss in 1H 2022)

Investor sentiment improves as stock rises 23%

First half 2023 earnings released: EPS: CN¥0.91 (vs CN¥3.08 loss in 1H 2022)

Hospital Corporation of China Limited to Report Q2, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Now 36% undervalued after recent price drop

New minor risk - Share price stability

Hospital Corporation of China Limited (HKG:3869) Stock Rockets 33% But Many Are Still Ignoring The Company

Full year 2022 earnings released: CN¥3.48 loss per share (vs CN¥2.03 loss in FY 2021)

Hospital Corporation of China Limited Announces Resignation of Lu Wenzuo as Executive Director

Less than half of directors are independent

First half 2022 earnings released: CN¥3.08 loss per share (vs CN¥2.47 loss in 1H 2021)

First half 2022 earnings released: CN¥3.09 loss per share (vs CN¥2.47 loss in 1H 2021)

Hospital Corporation of China Limited to Report Q2, 2022 Results on Aug 30, 2022

Hospital Corporation of China Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Hospital Corporation of China Limited, Annual General Meeting, Jun 22, 2022

Less than half of directors are independent

Full year 2021 earnings released: CN¥2.03 loss per share (vs CN¥2.93 loss in FY 2020)

Hospital Corporation of China Limited Announces Executive Changes

First half 2021 earnings released: CN¥2.47 loss per share (vs CN¥3.87 loss in 1H 2020)

Non Executive Director Zhiqiang Su has left the company

Hospital Corporation of China (HKG:3869) Hasn't Managed To Accelerate Its Returns

Full year 2020 earnings released: CN¥2.93 loss per share (vs CN¥1.09 profit in FY 2019)

Does Hospital Corporation of China (HKG:3869) Have A Healthy Balance Sheet?

Full year 2020 earnings released: CN¥2.93 loss per share (vs CN¥1.09 profit in FY 2019)

Hospital Corporation of China Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Would Shareholders Who Purchased Hospital Corporation of China's (HKG:3869) Stock Three Years Be Happy With The Share price Today?

New 90-day high: HK$11.38

Hospital Corporation of China Limited Announces Executive Changes

Should You Be Impressed By Hospital Corporation of China's (HKG:3869) Returns on Capital?

New 90-day low: HK$10.60

New 90-day low: HK$10.90

Hospital Corporation of China (HKG:3869) Takes On Some Risk With Its Use Of Debt

Hospital Corporation of China Limited Announces Management Changes

First half earnings released

Hospital Corporation of China Limited to Report First Half, 2020 Results on Aug 28, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento